Australian biotech market watch 01/06/09
Monday, 01 June, 2009
All Ordinaries are up across the board by 1.5% as further signs of recovery were being warmly welcomed by stock markets around the world. In line with the rise, health indices are up 1.1% after high volumes of trading compared to a fairly deflated week last week. CSL Limited (ASX:CSL) up 45c to $29.65 on the back of the US Government placing a $230 million dollar order to produce Novel A (H1N1) influenza vaccine antigen. Other risers include Probiotec (ASX:PBP), up 11c to $1.86 and Sonic Healthcare (ASX:SHL), which lifted 2.5% to $12.12. Flurotechnics bucked the trend, plummeting a dramatic 64.3% to 25c and CathRx (ASX:CXD) dropped 4c to 51c after releasing its quarterly investor update.
Proposed Australian trial eyes up blood testing for Alzheimer's
Utilising networks of GPs across three states, a large-scale study intends on combining digital...
Applications open for $300K pandemic therapeutics fellowships
Applications are now open for the Cumming Global Centre for Pandemic Therapeutics' inaugural...
CTA granted for CAR-T cell therapy for multiple myeloma
The Therapeutic Goods Administration has granted Clinical Trial Approval for KMCAR T-cell...
